Evidence map›Paper›PMID 25755423›Full record

ArticleJournal of clinical and experimental hepatology2012

Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Anil Arora, Praveen Sharma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Nutrients · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. [Diagnostic value of liver stiffness measurement for the evaluation of liver fibrosis in nonalcoholic fatty liver].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Treatment of NASH: What Helps Beyond Weight Loss?The American journal of gastroenterology · 2017
    Article
  16. Observational
  17. Article
  18. Article
  19. Hepatobiliary quiz-3 (2012).Journal of clinical and experimental hepatology · 2012
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anil AroraDepartments of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, India.
Praveen SharmaDepartments of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed as well as in developing countries. Its prevalence continues to rise currently affecting approximately 20-30% of adults and 10% of children in the United States. Non-alcoholic fatty liver disease represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign non-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease. Liver biopsy remains the gold standard for evaluating the degree of hepatic necroinflammation and fibrosis; however, several non-invasive investigations, such as serum biomarkers, have been developed to establish the diagnosis and also to evaluate treatment response. There has been a substantial development of non-invasive risk scores, biomarker panels, and radiological modalities to identify at risk patients with NAFLD without recourse to liver biopsy on a routine basis. Examples include combination of serum markers like NAFLD fibrosis score (NFS), BARD score, fibrometer, FIB4, and non-invasive tools like fibroscan which assess fibrosis in patients with NAFLD. Other markers of fibrosis that have been evaluated include high-sensitivity C-reactive protein, plasma pentraxin 3, interleukin-6, and cytokeratin-18. This review focuses on the methods currently available in daily clinical practice in hepatology and touches briefly on the potential future markers under investigation.

Indexed as

ALP, alkaline phosphatiseALT, alanine aminotransferaseAPRI, AST to platelet ratio indexAST, aspartate aminotransferaseAUCs, area under the curvesAUROC, area under the receiver-operating characteristics curveBMI, body mass indexCCL2, CC-chemokine ligand-2CI, confidence intervalCT, computed tomographyECM, extracellular matrixELF, European liver fibrosisFibrosisFT, FibroTestGGT, gamma-glutamyl-transpeptidaseHA, hyaluronic acidHTGC, hepatic triglyceride levelsLSM, liver stiffnessMRE, magnetic resonance elastographyMRI, magnetic resonance imagingMRS, magnetic resonance spectroscopyNAFLDNAFLD, non-alcoholic fatty liver diseaseNAFL, non-alcoholic fatty liverNASHNASH, non-alcoholic steatohepatitisNFS, NAFLD fibrosis scoreNPV, negative-predictive valueOR, odds ratioPPV, positive-predictive valueSF, serum ferritinSPEA, Serum prolidase enzyme activityTE, transient elastographyTIMP1, tissue inhibitor of metalloproteinase 1TNF, tumor necrosis factorTRX, thioredoxinUS, ultrasonography

Identifiers

PMID25755423
PMCPMC3940242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.